Infinium Pharmachem Approves Annual Financial Results and Audited Standalone/Consolidated Reports

Infinium Pharmachem Approves Annual Financial Results and Audited Standalone/Consolidated Reports​

Infinium Pharmachem Limited’s Board of Directors convened a meeting on May 29, 2026, where the company approved its annual audited financial results and statements for the year ended March 31, 2026. During the board meeting, the directors considered and approved the Annual Audited Standalone and Consolidated Financial Statements, along with the draft Auditors' Report for the same period.

The board meeting also reviewed operational and compliance matters, including the Statement of Deviation and variation in utilization of funds raised through IPO and Preferential issue for the half year ended March 31, 2026. The directors noted that the company maintained transparency, confirming no deviation in the utilization of raised funds. Furthermore, the board approved criteria for granting omnibus approval for related party transactions for the Financial Year 2026-27 and noted the CSR contribution made by the Company during the Financial Year 2025-26.

Financial Performance Review​

The audited financial results for the year ended March 31, 2026, were presented in both standalone and consolidated formats, alongside corresponding cash flow statements.

Standalone Financial Results (Year Ended March 31, 2026)​

The standalone financial results show a total income of 15705.65 Rs. In Lacs for the year ended March 31, 2026, compared to 13904.58 Rs. In Lacs in the previous year. Total expenses for the period reached 14434.19 Rs. In Lacs.

The profit before taxes for the full year stood at 135146 Rs. In Lacs, resulting in a profit for the period of 1001.74 Rs. In Lacs. Earnings per basic equity share for the full year were reported at 6.43, and diluted earnings per equity share were 143.

For comparison, the financials for the half-year period ended March 31, 2026, indicated a total income of 8486.95 Rs. In Lacs.

Consolidated Financial Results (Year Ended March 31, 2026)​

The consolidated financial results for the year ended March 31, 2026, showed total income of 213.79 Rs. In Lacs. Total expenses amounted to 19176.96 Rs. In Lacs, leading to a profit before taxes of 1784.04 Rs. In Lacs.

The profit (loss) for the period was 1215.02 Rs. In Lacs, with basic earnings per weighted average equity share reaching 7.80, and diluted earnings per weighted average equity share also reported at 7.80.

The financial statements are compiled based on the results of subsidiaries including Infinium Green Energy Private Limited, Infinium Healthcare Private Limited, and Shanghai Tajilin Industrial Co. Limited.

Balance Sheet Summary (Rs. In Lacs)​

The company’s audited consolidated balance sheet for the year ended March 31, 2026, reflected a total assets figure of 17493.60. This compares to 19838.52 for the year ended March 31, 2025.

The equity and liabilities section totaled 17493.60.

Audit Opinion​

The Statutory Auditors, Ashok Rajpara & Co., Chartered Accountants, issued an opinion confirming that the Annual Audited Standalone and Annual Audited Consolidated financial results for the year ended March 31, 2026, carry an unmodified opinion.

The company confirmed that the auditors provided an audit report with an unmodified opinion on both the audited standalone and consolidated financial results for the period ended March 31, 2026.

INFINIUM Stock Price Movement​

Infinium Pharmachem Limited shares today slipped by 0.21% to settle at ₹213.75. The stock concluded its trading day with a relatively light volume of 5,500 shares.